Hospital Universitario Araba-ko ikertzaileekin lankidetzan egindako argitalpenak (25)

2024

  1. Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19

    Blood Cancer Journal, Vol. 14, Núm. 1

2021

  1. Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies

    Blood Cancer Journal, Vol. 11, Núm. 12

  2. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

    Blood Cancer Journal, Vol. 11, Núm. 5

  3. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations

    British Journal of Haematology, Vol. 194, Núm. 4, pp. 708-717

2017

  1. Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes

    Cancer Letters, Vol. 409, pp. 42-48

  2. Monosomal karyotype in chronic lymphocytic leukemia: Association with clinical and biological features and potential prognostic significance

    American Journal of Hematology

  3. Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions

    Oncotarget, Vol. 8, Núm. 33, pp. 54297-54303

2016

  1. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations

    Oncotarget, Vol. 7, Núm. 49, pp. 80916-80924

  2. Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes

    Genes Chromosomes and Cancer, Vol. 55, Núm. 4, pp. 322-327

2014

  1. Interstitial 13q14 deletions detected in the karyotype and translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia: Different genetic mechanisms but equivalent poorer clinical outcome

    Genes Chromosomes and Cancer, Vol. 53, Núm. 9, pp. 788-797

2013

  1. Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: Analysis of 627 patients with isolated 13q deletion

    British Journal of Haematology, Vol. 163, Núm. 1, pp. 47-54

  2. Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome

    Leukemia Research, Vol. 37, Núm. 7, pp. 769-776

  3. Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: Review of 5,654 patients with an evaluable karyotype

    Genes Chromosomes and Cancer, Vol. 52, Núm. 8, pp. 753-763

2011

  1. Cytogenetic risk stratification in chronic myelomonocytic leukemia

    Haematologica, Vol. 96, Núm. 3, pp. 375-383

2010

  1. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma

    Genes Chromosomes and Cancer, Vol. 49, Núm. 5, pp. 439-451

2007

  1. DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups

    Leukemia, Vol. 21, Núm. 6, pp. 1224-1231

2006

  1. Interphase FISH for the detection of breakpoints in IG loci and chromosomal changes with adverse prognostic impact in multiple myeloma with normal karyotypes

    Cancer Genetics and Cytogenetics

2005

  1. Amplification of IGH/MYC fusion in clinically aggressive IGH/BCL2-positive germinal center B-cell lymphomas

    Genes Chromosomes and Cancer, Vol. 43, Núm. 4, pp. 414-423

2004

  1. Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: Two further cases

    Hematology Journal, Vol. 5, Núm. 6, pp. 534-537

  2. Cryptic ins(2;11) with clonal evolution showing amplification of 11q23-q25 either on hsr(11) or on dmin, in a patient with AML-M2 [4]

    Leukemia